Casdozokitug
1L Hepatocellular Carcinoma (combo with toripalimab + bevacizumab)
Key Facts
Indication
1L Hepatocellular Carcinoma (combo with toripalimab + bevacizumab)
Phase
Phase 2
Status
Ongoing
Company
About Coherus Oncology
Coherus Oncology is dedicated to extending patient survival through a portfolio of innovative immuno-oncology (I-O) combination therapies. The company has successfully commercialized LOQTORZI® and is advancing multiple clinical-stage candidates, including tagmokitug (anti-CCR8) and casdozokitug (IL-27 antagonist), across various solid tumors. With a leadership team of seasoned industry veterans and a strategic focus on novel I-O mechanisms, Coherus aims to transform cancer treatment by addressing key resistance pathways in the tumor microenvironment.
View full company profile